Get the Stockscreener App
2.1878
1.89%
-0.0422
After Hours:
2.19
0.0022
+0.10%
Collplant Biotechnologies Ltd stock is traded at $2.1878, with a volume of 13,447.
It is down -1.89% in the last 24 hours and down -5.29% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$2.23
Open:
$2.23
24h Volume:
13,447
Relative Volume:
0.14
Market Cap:
$27.82M
Revenue:
$2.47M
Net Income/Loss:
$-13.87M
P/E Ratio:
-1.7933
EPS:
-1.22
Net Cash Flow:
$-12.42M
1W Performance:
-1.45%
1M Performance:
-5.29%
6M Performance:
-35.65%
1Y Performance:
-48.50%
1-Day Range:
$2.1404
$2.25
1-Week Range:
$1.92
$2.25
52-Week Range:
$1.31
$4.98
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
2.1878 | 28.36M | 2.47M | -13.87M | -12.42M | -1.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
CLGN Analyst Rating Maintained: November 2025 Update | CLGN Stock News - GuruFocus
CollPlant Biotechnologies Reports Q3 2025 Financial Results - TipRanks
CollPlant Biotechnologies schedules annual and extraordinary meeting for December 31 - Investing.com
CollPlant Biotechnologies Announces Annual and Extraordinary General Meeting for December 2025 - TipRanks
[6-K] CollPlant Biotechnologies Ltd Current Report (Foreign Issuer) | CLGN SEC FilingForm 6-K - Stock Titan
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
CollPlant (CLGN) Sees Significant Q3 Revenue Growth and Advances in Bioprinting - GuruFocus
CLGN Stock Crashed 14% Today – Disappointing Earnings, Workforce Reduction Plan Draws Investor Attention - Stocktwits
CollPlant shares edge down as Q3 revenue falls short of estimates - Investing.com Australia
CollPlant shares edge down as Q3 revenue falls short of estimates By Investing.com - Investing.com South Africa
CollPlant Biotechnologies' Q3 revenue rises on rhCollagen sales, cuts workforce - TradingView
CLGN: Revenue and net loss improved year-over-year, with expanded North American operations and new product milestones - TradingView
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
CollPlant Biotechnologies's Earnings Outlook - Benzinga
Is CollPlant Biotechnologies Ltd a good long term investmentPrice Action Trading & Free Risk Assessment and Control - earlytimes.in
What analysts say about CollPlant Biotechnologies Ltd stockFundamental Stock Analysis & Fast Profit Trading Ideas - earlytimes.in
Can CollPlant Biotechnologies Ltd. stock sustain market leadership2025 Top Decliners & Growth Focused Stock Reports - newser.com
Is CollPlant Biotechnologies Ltd. (CPT) stock resilient in recession scenariosJuly 2025 Retail & Consistent Profit Trade Alerts - newser.com
Why CollPlant Biotechnologies Ltd. stock is rated strong buy2025 Market Overview & Long-Term Growth Stock Strategies - newser.com
How CollPlant Biotechnologies Ltd. stock trades during market volatility2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
Is CollPlant Biotechnologies Ltd. stock trading at a premium valuation2025 Retail Activity & Reliable Trade Execution Plans - newser.com
Why CollPlant Biotechnologies Ltd. (CPT) stock could be top winner2025 Retail Activity & Target Return Focused Stock Picks - newser.com
Is CollPlant Biotechnologies Ltd. forming a bottoming baseJuly 2025 Retail & Verified Momentum Watchlists - newser.com
How analysts rate CollPlant Biotechnologies Ltd. stock today2025 Market WrapUp & Verified Momentum Stock Watchlist - newser.com
When is the best time to exit CollPlant Biotechnologies Ltd.Weekly Trading Summary & Advanced Swing Trade Entry Alerts - newser.com
How to forecast CollPlant Biotechnologies Ltd. trends using time seriesQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
CollPlant Biotechnologies (CLGN) to Release Earnings on Wednesday - Defense World
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS - MarketScreener
CollPlant Biotechnologies (NASDAQ: CLGN) to report third quarter 2025 results Nov. 26 - Stock Titan
How CollPlant Biotechnologies Ltd. stock benefits from tech adoptionMarket Trend Summary & Risk Managed Investment Signals - newser.com
Will CollPlant Biotechnologies Ltd. (CPT) stock benefit from commodity supercycle2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
Will CollPlant Biotechnologies Ltd. stock go up soonJuly 2025 Fed Impact & Smart Investment Allocation Tips - newser.com
What Wall Street predicts for CollPlant Biotechnologies Ltd. stock priceQuarterly Performance Summary & Target Return Focused Stock Picks - newser.com
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):